Compare DexCom, Inc. (DXCM) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Harley-Davidson Inc — how do they compare? DexCom, Inc. trades at $90.83 (market cap $33.79B), while Harley-Davidson Inc trades at $26.03 (market cap $2.78B). The key difference: DexCom, Inc. is far larger — about 12.2× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | HOG | |
|---|---|---|
Market Cap | $33.79B | $2.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $31.03 |
52-Week Low | $54.84 | $17.19 |
Enterprise Value | $33.24B | $3.19B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Harley-Davidson (HOG) trades at $25.95, down 0.57% with a bullish technical signal. The company reported Q2 2026 EPS of $0.75 beating estimates of $0.645, though revenue declined to $4.47B in 2025 from $5.8B in 2022. Valuation metrics appear reasonable with P/E of 14.84 and P/S of 0.72. Recent news highlights production returning to US facilities and raised 2026 guidance following stronger North American sales.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include cost-cutting initiatives and domestic production advantages, while risks involve ongoing revenue pressure, competitive threats from Indian Motorcycle, and margin compression from rising raw material costs evident in recent quarterly results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
